2022 Q3 Form 10-Q Financial Statement
#000149315222033843 Filed on November 28, 2022
Income Statement
Concept | 2022 Q3 | 2021 Q3 |
---|
Balance Sheet
Concept | 2022 Q3 | 2021 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $0.00 | $67.33K |
YoY Change | -100.0% | |
Cash & Equivalents | $67.33K | |
Short-Term Investments | ||
Other Short-Term Assets | $40.00K | |
YoY Change | ||
Inventory | $24.00K | |
Prepaid Expenses | ||
Receivables | $54.25K | |
Other Receivables | $89.51K | |
Total Short-Term Assets | $167.8K | $381.0K |
YoY Change | -55.97% | |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $501.8K | $417.6K |
YoY Change | 20.16% | |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | ||
YoY Change | ||
Total Long-Term Assets | $1.970M | $1.919M |
YoY Change | 2.67% | |
TOTAL ASSETS | ||
Total Short-Term Assets | $167.8K | $381.0K |
Total Long-Term Assets | $1.970M | $1.919M |
Total Assets | $2.137M | $2.300M |
YoY Change | -7.05% | |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $981.3K | $112.5K |
YoY Change | 772.42% | |
Accrued Expenses | $893.4K | $441.3K |
YoY Change | 102.45% | |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $1.398M | $5.711M |
YoY Change | -75.52% | |
Long-Term Debt Due | $4.320M | |
YoY Change | ||
Total Short-Term Liabilities | $7.876M | $6.311M |
YoY Change | 24.78% | |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $378.5K | $148.6K |
YoY Change | 154.65% | |
Other Long-Term Liabilities | $197.2K | |
YoY Change | ||
Total Long-Term Liabilities | $575.7K | $148.6K |
YoY Change | 287.36% | |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $7.876M | $6.311M |
Total Long-Term Liabilities | $575.7K | $148.6K |
Total Liabilities | $8.451M | $6.460M |
YoY Change | 30.82% | |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$12.23M | |
YoY Change | ||
Common Stock | $231.5K | |
YoY Change | ||
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | -$6.314M | -$4.161M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $2.137M | $2.300M |
YoY Change | -7.05% |
Cashflow Statement
Concept | 2022 Q3 | 2021 Q3 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022Q1 | OMWS |
Secured Debts
SecuredDebts
|
usd | |
CY2022Q3 | us-gaap |
Secured Debt
SecuredDebt
|
usd | |
CY2022Q1 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
usd | |
CY2022Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
OMWS |
Bad Debt Expense
BadDebtExpense
|
usd | ||
us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
usd | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
usd | ||
OMWS |
Increase Decrease In Deposit Liability
IncreaseDecreaseInDepositLiability
|
usd | ||
CY2022Q3 | us-gaap |
Deposit Liability Current
DepositLiabilityCurrent
|
usd | |
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
usd | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
usd | ||
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
usd | ||
us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
usd | ||
OMWS |
Payment For Subscriptions Receivable
PaymentForSubscriptionsReceivable
|
usd | ||
CY2022Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
usd | |
OMWS |
Payment For Subscriptions Receivable
PaymentForSubscriptionsReceivable
|
usd | ||
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
usd | ||
OMWS |
Product Warranty Expenses
ProductWarrantyExpenses
|
usd | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001676852 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--03-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
usd | |
OMWS |
Product Warranty Expenses
ProductWarrantyExpenses
|
usd | ||
CY2022Q3 | OMWS |
Product Warranty Expenses
ProductWarrantyExpenses
|
usd | |
CY2021Q3 | OMWS |
Product Warranty Expenses
ProductWarrantyExpenses
|
usd | |
us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
usd | ||
CY2021Q3 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
usd | |
OMWS |
Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
|
usd | ||
OMWS |
Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
|
usd | ||
CY2022Q3 | OMWS |
Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
|
usd | |
CY2021Q3 | OMWS |
Other Selling General And Administrative Expense Related Party
OtherSellingGeneralAndAdministrativeExpenseRelatedParty
|
usd | |
OMWS |
Consulting Expense
ConsultingExpense
|
usd | ||
CY2021Q3 | OMWS |
Consulting Expense
ConsultingExpense
|
usd | |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
usd | ||
CY2021Q3 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
usd | |
OMWS |
Royalty Expense Income
RoyaltyExpenseIncome
|
usd | ||
CY2021Q3 | OMWS |
Royalty Expense Income
RoyaltyExpenseIncome
|
usd | |
OMWS |
License Royalties
LicenseRoyalties
|
usd | ||
OMWS |
License Royalties
LicenseRoyalties
|
usd | ||
CY2022Q3 | OMWS |
License Royalties
LicenseRoyalties
|
usd | |
CY2021Q3 | OMWS |
License Royalties
LicenseRoyalties
|
usd | |
CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
usd | |
OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
usd | ||
CY2022Q3 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
usd | |
us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | ||
us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | ||
CY2022Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | |
CY2021Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | |
CY2022Q2 | OMWS |
Reclass Par Value Of Shares And Shares Outstanding
ReclassParValueOfSharesAndSharesOutstanding
|
usd | |
us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | ||
us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
usd | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
usd | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
usd | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
usd | ||
OMWS |
Amortization Of Warrants
AmortizationOfWarrants
|
usd | ||
OMWS |
Amortization Of Warrants
AmortizationOfWarrants
|
usd | ||
OMWS |
Discount On Notes
DiscountOnNotes
|
usd | ||
OMWS |
Discount On Notes
DiscountOnNotes
|
usd | ||
OMWS |
Royalty On Sales
RoyaltyOnSales
|
usd | ||
OMWS |
Finance Costs Related To Note Payable
FinanceCostsRelatedToNotePayable
|
usd | ||
OMWS |
Finance Costs Related To Note Payable
FinanceCostsRelatedToNotePayable
|
usd | ||
OMWS |
Finance Costs Paid In Stock
FinanceCostsPaidInStock
|
usd | ||
OMWS |
Finance Costs Paid In Stock
FinanceCostsPaidInStock
|
usd | ||
OMWS |
Gain Loss On Ppp Loan Forgiven
GainLossOnPppLoanForgiven
|
usd | ||
OMWS |
Rent Payments On Lease Liability
RentPaymentsOnLeaseLiability
|
usd | ||
OMWS |
Bad Debt Expense
BadDebtExpense
|
usd | ||
us-gaap |
Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
|
usd | ||
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
usd | ||
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
usd | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
|
usd | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
usd | |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
usd | |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
usd | |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
usd | |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
333-211986 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
OMNIA WELLNESS INC | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
98-1291924 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
999 18th Street | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 3000 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Denver | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CO | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
80202 | ||
dei |
City Area Code
CityAreaCode
|
(888) | ||
dei |
Local Phone Number
LocalPhoneNumber
|
320-5711 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2022Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
231505146 | shares |
CY2022Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1894 | usd |
CY2022Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
54251 | usd |
CY2022Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
118349 | usd |
CY2022Q3 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
89505 | usd |
CY2022Q1 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
91380 | usd |
CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
24000 | usd |
CY2022Q1 | us-gaap |
Inventory Net
InventoryNet
|
24000 | usd |
CY2022Q3 | us-gaap |
Assets Current
AssetsCurrent
|
167756 | usd |
CY2022Q1 | us-gaap |
Assets Current
AssetsCurrent
|
235623 | usd |
CY2022Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
501778 | usd |
CY2022Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
515113 | usd |
CY2022Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1350850 | usd |
CY2022Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1450900 | usd |
CY2022Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
117098 | usd |
CY2022Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
160197 | usd |
CY2022Q3 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
1969726 | usd |
CY2022Q1 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
2126210 | usd |
CY2022Q3 | us-gaap |
Assets
Assets
|
2137482 | usd |
CY2022Q1 | us-gaap |
Assets
Assets
|
2361833 | usd |
CY2022Q3 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
981301 | usd |
CY2022Q1 | us-gaap |
Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
|
562213 | usd |
CY2022Q1 | us-gaap |
Deposit Liability Current
DepositLiabilityCurrent
|
8002 | usd |
CY2022Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
893443 | usd |
CY2022Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
615261 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
101465 | usd |
CY2022Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
99464 | usd |
CY2022Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
25667 | usd |
CY2022Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
25667 | usd |
CY2022Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
155289 | usd |
CY2022Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
143817 | usd |
CY2022Q3 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1852735 | usd |
CY2022Q1 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
1102735 | usd |
CY2022Q3 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
1792566 | usd |
CY2022Q1 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
1765219 | usd |
CY2022Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
29970 | usd |
CY2022Q1 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
29970 | usd |
CY2022Q3 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
1368193 | usd |
CY2022Q1 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
1229443 | usd |
CY2022Q3 | OMWS |
Secured Debts
SecuredDebts
|
675000 | usd |
CY2022Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7875629 | usd |
CY2022Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5581791 | usd |
CY2022Q3 | OMWS |
Due To Related Party Noncurrent
DueToRelatedPartyNoncurrent
|
163239 | usd |
CY2022Q1 | OMWS |
Due To Related Party Noncurrent
DueToRelatedPartyNoncurrent
|
143239 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
33997 | usd |
CY2022Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
80099 | usd |
CY2022Q1 | us-gaap |
Secured Debt
SecuredDebt
|
675000 | usd |
CY2022Q3 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
141920 | usd |
CY2022Q1 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
891920 | usd |
CY2022Q3 | OMWS |
Nonconvertible Notes Non Related
NonconvertibleNotesNonRelated
|
166571 | usd |
CY2022Q1 | OMWS |
Nonconvertible Notes Non Related
NonconvertibleNotesNonRelated
|
189918 | usd |
CY2022Q3 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
70000 | usd |
CY2022Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
575727 | usd |
CY2022Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
1980176 | usd |
CY2022Q3 | us-gaap |
Liabilities
Liabilities
|
8451356 | usd |
CY2022Q1 | us-gaap |
Liabilities
Liabilities
|
7561967 | usd |
CY2022Q3 | OMWS |
Stock Payable
StockPayable
|
230367 | usd |
CY2022Q1 | OMWS |
Stock Payable
StockPayable
|
642867 | usd |
CY2022Q3 | OMWS |
Stock Reserve
StockReserve
|
412500 | usd |
CY2022Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
150000000 | shares |
CY2022Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
150000000 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1500000000 | shares |
CY2022Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1500000000 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
231505146 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
231505146 | shares |
CY2022Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
232222818 | shares |
CY2022Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
232222818 | shares |
CY2022Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
231505 | usd |
CY2022Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
232223 | usd |
CY2022Q3 | OMWS |
Common Stock Subscribed Par Or Stated Value Per Share
CommonStockSubscribedParOrStatedValuePerShare
|
0.001 | |
CY2022Q1 | OMWS |
Common Stock Subscribed Par Or Stated Value Per Share
CommonStockSubscribedParOrStatedValuePerShare
|
0.001 | |
CY2022Q3 | OMWS |
Common Stock Subscribed Shares Outstanding
CommonStockSubscribedSharesOutstanding
|
2500000 | shares |
CY2022Q1 | OMWS |
Common Stock Subscribed Shares Outstanding
CommonStockSubscribedSharesOutstanding
|
0 | shares |
CY2022Q3 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
2500 | usd |
CY2022Q1 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
2500 | usd |
CY2022Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
5445438 | usd |
CY2022Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
5344318 | usd |
CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-12226184 | usd |
CY2022Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-11012042 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
410000 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
410000 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6313874 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-5200134 | usd |
CY2022Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
2137482 | usd |
CY2022Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
2361833 | usd |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
162092 | usd | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
94931 | usd | |
CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
28446 | usd |
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
57809 | usd |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
98500 | usd | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
15010 | usd | |
CY2022Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
77534 | usd |
CY2021Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8477 | usd |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
98500 | usd | |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
15010 | usd | |
CY2022Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
77534 | usd |
CY2021Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
8477 | usd |
us-gaap |
Gross Profit
GrossProfit
|
63592 | usd | |
us-gaap |
Gross Profit
GrossProfit
|
79921 | usd | |
CY2022Q3 | us-gaap |
Gross Profit
GrossProfit
|
-49088 | usd |
CY2021Q3 | us-gaap |
Gross Profit
GrossProfit
|
49332 | usd |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
190783 | usd | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
143036 | usd | |
us-gaap |
Professional Fees
ProfessionalFees
|
356002 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1536678 | usd | |
CY2022Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
95448 | usd |
CY2021Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
72557 | usd |
us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
6000 | usd | |
CY2022Q3 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
6000 | usd |
us-gaap |
Professional Fees
ProfessionalFees
|
85559 | usd | |
CY2022Q3 | us-gaap |
Professional Fees
ProfessionalFees
|
83780 | usd |
CY2021Q3 | us-gaap |
Professional Fees
ProfessionalFees
|
255048 | usd |
us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
219501 | usd | |
us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
84104 | usd | |
CY2022Q3 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
88230 | usd |
CY2021Q3 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
58937 | usd |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
20779 | usd | |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
30920 | usd | |
CY2022Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2220 | usd |
CY2021Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
30544 | usd |
OMWS |
Consulting Expense
ConsultingExpense
|
44180 | usd | |
CY2022Q3 | OMWS |
Consulting Expense
ConsultingExpense
|
27239 | usd |
us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
91000 | usd | |
CY2022Q3 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
45000 | usd |
OMWS |
Royalty Expense Income
RoyaltyExpenseIncome
|
-11472 | usd | |
CY2022Q3 | OMWS |
Royalty Expense Income
RoyaltyExpenseIncome
|
3805 | usd |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
150096 | usd | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
68412 | usd | |
CY2022Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
64776 | usd |
CY2021Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9184 | usd |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
48200 | usd | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
732000 | usd | |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
397500 | usd |
us-gaap |
Operating Expenses
OperatingExpenses
|
867570 | usd | |
us-gaap |
Operating Expenses
OperatingExpenses
|
1414474 | usd | |
CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
408889 | usd |
CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
823770 | usd |
OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
443873 | usd | |
CY2021Q3 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
146959 | usd |
us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
410164 | usd | |
us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
1045638 | usd | |
CY2022Q3 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
176640 | usd |
CY2021Q3 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
918807 | usd |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-410164 | usd | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-601765 | usd | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-176640 | usd |
CY2021Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-771848 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-1214142 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-1936318 | usd | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-634617 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1546286 | usd |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | ||
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.00 | |
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
231507112 | shares | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
224213846 | shares | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
231509068 | shares |
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
224213846 | shares |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3408641 | usd |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
430123 | usd |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-390032 | usd |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3368550 | usd |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
754291 | usd |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1546286 | usd |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-4160545 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-5200134 | usd |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
77561 | usd |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-579526 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-5702099 | usd |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-5702099 | usd |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
22841 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-634617 | usd |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-634617 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6313874 | usd |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6313874 | usd |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-1214142 | usd | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-1936318 | usd | |
us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
147685 | usd | |
us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
143576 | usd | |
OMWS |
Convertibles Notes Convertible Beneficial Conversion Feature
ConvertiblesNotesConvertibleBeneficialConversionFeature
|
100402 | usd | |
OMWS |
Convertibles Notes Convertible Beneficial Conversion Feature
ConvertiblesNotesConvertibleBeneficialConversionFeature
|
771576 | usd | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
43099 | usd | |
OMWS |
Royalty On Sales
RoyaltyOnSales
|
11472 | usd | |
OMWS |
Gain Loss On Ppp Loan Forgiven
GainLossOnPppLoanForgiven
|
440266 | usd | |
OMWS |
Rent Payments On Lease Liability
RentPaymentsOnLeaseLiability
|
44101 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-64098 | usd | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
72418 | usd | |
us-gaap |
Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
|
-1875 | usd | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
24000 | usd | |
OMWS |
Increase Decrease In Deposit Liability
IncreaseDecreaseInDepositLiability
|
8002 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
449088 | usd | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
7771 | usd | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
278182 | usd | |
us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
13401 | usd | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-170344 | usd | |
us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
212750 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
34300 | usd | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
146750 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-34300 | usd | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-146750 | usd | |
OMWS |
Proceeds From Advances
ProceedsFromAdvances
|
20000 | usd | |
us-gaap |
Proceeds From Short Term Debt
ProceedsFromShortTermDebt
|
1309154 | usd | |
OMWS |
Payments On Advances
PaymentsOnAdvances
|
30000 | usd | |
OMWS |
Payments For Decrease In Stock Subscription Payable
PaymentsForDecreaseInStockSubscriptionPayable
|
412500 | usd | |
OMWS |
Proceeds From Increase In Stock Reserve
ProceedsFromIncreaseInStockReserve
|
412500 | usd | |
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
718 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
-718 | usd | |
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
412839 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
202750 | usd | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1721993 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1894 | usd | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
38565 | usd | |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1894 | usd |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
28761 | usd |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
0 | usd |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
67326 | usd |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_801_eus-gaap--NatureOfOperations_zgmZHVgYrOn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Note 1 <span id="xdx_822_zUlEHaVgJhnc">Nature of Operations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Omnia Wellness Inc. (the “Company”) was incorporated as a Nevada corporation on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_c20220401__20220930_zhLlIN5ef2Jh" title="Entity incorporation, date of incorporation">March 2, 2016</span>, by the filing of articles of incorporation with the Secretary of State of the State of <span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20220401__20220930_zTrCrCWwX1W7" title="Entity incorporation, state or country code">Nevada</span> under the name Glolex, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220401__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MaksimCharniakMember_zdFDn6ULBWl4" title="Equity method investment description">On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20190624__20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zq3M6MNDkIBl" title="Stock split shares">3,000,000</span> shares (pre- stock split) of the Company’s common stock, sold all his shares of common stock of the Company to Amer Samad, resulting in a change of control of the Company. As part of that transaction, Mr. Charniak resigned from all of his officer and director positions, and Mr. Samad was appointed as the Chief Executive Officer, President, Chief Financial Officer and Secretary of the Company, and was appointed to the Board of Directors of the Company. Mr. Samad also purchased 1,167,937 shares (pre-stock split) of the Company’s common stock in a series of private transactions, resulting in Mr. Samad owning 4,167,937 shares (pre-stock split) of the Company’s common stock, or approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190625__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MrAmerSamadMember_zYq2bmCjikki" title="Ownership percentage">95.6</span>% of the issued and outstanding common stock of the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2020, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to, among other things, (i) increase the Company’s authorized shares of common stock from <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20200304_zYNMxwXkLvRb" title="Common stock, shares authorized">75,000,000</span> to <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20200305_zkDRxXsvcll5" title="Common stock, shares authorized">100,000,000</span>, (ii) create and authorize <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20200305__srt--StatementScenarioAxis__custom--BlankCheckMember_zqBrB67ouOa5" title="Preferred stock authorized">10,000,000</span> shares of “blank check” preferred stock, and (iii) effect a <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20200303__20200305_z1Ia8OqZYN1j" title="Forward stock split">12.6374:1</span> forward stock split of the common stock. In addition, on March 16, 2020, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change the name of the Company from Glolex Inc. to Omnia Wellness Inc. On April 15, 2020, the stock of the Company began trading on the OTC Pink market under the symbol “OMWS”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 17, 2020, the Company entered into a Share Exchange and Reorganization Agreement (the “Exchange Agreement”) with Omnia Wellness Corporation (formerly known as Bed Therapies Inc.), a Texas corporation (“Omnia Corp.”), and the beneficial stockholders of Omnia Corp. to acquire <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zlyvUWGUHQ95" title="Ownership percentage">100</span>% of the issued and outstanding shares of capital stock of Omnia Corp. The transactions contemplated by the Exchange Agreement were consummated on January 5, 2021, and, pursuant to the terms of the Exchange Agreement, among other things, all outstanding shares of common stock of Omnia Corp., no par value, or the Omnia Corp. Shares, were exchanged for shares of the Company’s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zoVvTfRZiGf1" title="Common stock, par value">0.001</span> per share, based on the exchange ratio of one share of the Company’s common stock for every one Omnia Corp. Share. The Company refers herein to the transactions contemplated by the Exchange Agreement, collectively, as the Acquisition. <span id="xdx_903_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zFbNEAsBm4f8" title="Forward stock split description">Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel <span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zCvzOz7isHW8" title="Cancellation of stock split">52,656,888</span></span> (pre-stock split) shares of the Company’s common stock owned beneficially and of record by him as part of the conditions to Closing, which were cancelled immediately following the Closing. The Company also issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20210104__20210105__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zT66TGEC1Zpj" title="Stock issued during period shares stock splits">1,269,665</span> (pre-stock split) shares of common stock on January 5, 2021, as a result of the conversion in accordance with their terms of outstanding convertible promissory notes in the aggregate principal amount of approximately $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20200416__20200417__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BedTherapiesIncMember_zDJVV05CQv7k" title="Debt conversion, converted instrument, amount">539,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with RZI Consulting LLC (the “Assignment Agreement”), pursuant to which RZI Consulting LLC assumed substantially all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, the Company had no assets or liabilities (other than relating to general and administrative expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Acquisition, the Company, through its wholly owned subsidiary Omnia Corp., now develops and markets products for wellness and physical therapy markets, using patented dry-hydro therapy equipment that the Company plans to offer and sell in medical and fitness markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 6, 2021, <span id="xdx_909_eus-gaap--StockholdersEquityNoteStockSplit_c20210404__20210406__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--BedTherapiesIncMember__srt--TitleOfIndividualAxis__custom--MrAmerSamadMember_zaQdQpmmp74d" title="Stockholders equity description">the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_z8f6rd6SIv16" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_ztkU7AsbxA4j" title="Common stock, shares authorized">1,500,000,000</span>, (ii) increase the Company’s authorized shares of “blank check” preferred stock from <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MinimumMember_zRzw20wuMsgb" title="Preferred stock authorized">10,000,000</span> to <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20210406__srt--RangeAxis__srt--MaximumMember_z9PO49G1DZha" title="Preferred stock authorized">150,000,000</span>, and (iii) effect a 1:15 forward stock split of the common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal executive office is located at 999 18<sup>th</sup> St., Suite 3000, Denver, CO 80202, and its telephone number is 303-325-3738. The Company’s website address is www.omniawellness.com.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020 the World Health Organization declared COVID-19 a pandemic. The Company is still assessing the impact COVID-19 may have on its business, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2016-03-02 | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | ||
CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | shares |
CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2020Q1 | us-gaap |
Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
|
12.6374:1 | |
us-gaap |
Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
|
The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. | ||
CY2019Q2 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P10Y | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
100050 | usd | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_849_eus-gaap--UseOfEstimates_zUAn5v8AX5of" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zXb6z61wEhEl">Accounting Estimates</span> </i></b>- The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: the allowance for doubtful accounts, determination of impairment on investments and determination of recoverability of deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zNKmbSKSHQbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zN4ZurRzMeA1">Risks and Uncertainties</span></i></b> - The Company’s operations may be subject to significant risk and uncertainties including financial, operational, regulatory, and other risks associated with a start-up company, including the potential risk of business failure. See Note 3 regarding going concern matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
231505146 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
224227107 | shares | |
CY2022Q3 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
54251 | usd |
CY2021Q3 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
66950 | usd |
us-gaap |
Depreciation
Depreciation
|
147684 | usd | |
us-gaap |
Depreciation
Depreciation
|
143036 | usd | |
CY2019Q2 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
350000 | usd |
CY2019Q2 | us-gaap |
Payments Of Loan Costs
PaymentsOfLoanCosts
|
1000 | usd |
CY2019Q4 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
200000 | usd |
CY2022Q3 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
0 | usd |
CY2021Q3 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
40000 | usd |
CY2022Q3 | us-gaap |
Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
|
241854 | usd |
CY2021Q3 | us-gaap |
Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
|
169230 | usd |
us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P10Y | ||
CY2022Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
650150 | usd |
CY2021Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
500075 | usd |
CY2020Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
1450000 | usd |
CY2022Q3 | OMWS |
Royalty Liability
RoyaltyLiability
|
32808 | usd |
CY2022Q3 | OMWS |
Monthly Sales Percent
MonthlySalesPercent
|
0.05 | pure |
CY2022Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
892004 | usd |
CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
669304 | usd |
CY2022Q3 | OMWS |
Property Plant And Equipment And Intangible Assets Net
PropertyPlantAndEquipmentAndIntangibleAssetsNet
|
1852628 | usd |
CY2021Q3 | OMWS |
Property Plant And Equipment And Intangible Assets Net
PropertyPlantAndEquipmentAndIntangibleAssetsNet
|
1918527 | usd |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
100050 | usd | |
CY2022Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
135462 | usd |
us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
Our assessment is based on (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period and (3) whether we have the right to direct the use of the asset. Leases are classified as either finance leases or operating leases. | ||
CY2022Q3 | us-gaap |
Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
|
147363 | usd |
CY2022Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
117098 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
101465 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
33997 | usd |
CY2022Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
135462 | usd |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
44101 | usd | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
8080 | usd | |
CY2021 | us-gaap |
Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
|
1.0 | pure |
CY2021Q2 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
294066 | usd |
CY2021Q3 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
146200 | usd |
CY2021Q4 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
148625 | usd |
CY2022Q1 | OMWS |
Gain On Ppp Loan Forgiven
GainOnPppLoanForgiven
|
593546 | usd |
CY2021Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
513827 | usd |
us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
1014478 | usd | |
us-gaap |
Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
|
771576 | usd | |
CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1500000000 | shares |
CY2022Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | usd | |
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | usd | |
us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | usd | |
us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | usd | |
CY2022Q3 | us-gaap |
Area Of Land
AreaOfLand
|
200 | sqft |